Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 15, 2019

SELL
$6.71 - $8.6 $68,260 - $87,487
-10,173 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$6.27 - $10.92 $63,784 - $111,089
10,173 New
10,173 $77,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $357M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Weiss Asset Management LP Portfolio

Follow Weiss Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Asset Management LP with notifications on news.